Francesco Bertoni

List of Publications by Year
in descending order

387 papers	19,014 citations	11608 70 h-index	16127 124 g-index
404 all docs	404 docs citations	404 times ranked	19801 citing authors

#	Article	IF	Citations
1	Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1â€“polarizing program in dendritic cells. Nature Immunology, 2005, 6, 769-776.	7.0	1,044
2	Mutations of multiple genes cause deregulation of NF-ÎºB in diffuse large B-cell lymphoma. Nature, 2009, 459, 717-721.	13.7	969
3	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. Journal of Experimental Medicine, 2011, 208, 1389-1401.	4.2	565
4	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood, 2013, 121, 1403-1412.	0.6	420
5	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 516-532.	7.7	378
6	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. Journal of Experimental Medicine, 2012, 209, 1537-1551.	4.2	363
7	BET Proteins as Targets for Anticancer Treatment. Cancer Discovery, 2018, 8, 24-36.	7.7	345
8	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood, 2011, 118, 6904-6908.	0.6	342
9	Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Annals of Oncology, 1997, 8, 727-737.	0.6	332
10	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, 2011, 117, 3391-3401.	0.6	316
11	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Antiâ€“Helicobacter Pylori Therapy. Journal of Clinical Oncology, 2005, 23, 1979-1983.	0.8	265
12	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood, 2012, 119, 2854-2862.	0.6	257
13	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research, 2015, 21, 1628-1638.	3.2	237
14	The NF-ÎºB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood, 2009, 113, 4918-4921.	0.6	232
15	Molecular Analysis of the Progression fromHelicobacter pyloriâ€“Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach. New England Journal of Medicine, 1998, 338, 804-810.	13.9	230
16	Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human Pathology, 2000, 31, 263-268.	1.1	227
17	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood, 2018, 131, 2413-2425.	0.6	223
18	The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood, 2016, 127, 2082-2092.	0.6	219

#	Article	IF	Citations
19	The gastric marginal zone B-cell lymphoma of MALT type. Blood, 2000, 96, 410-419.	0.6	214
20	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood, 2013, 122, 2673-2682.	0.6	208
21	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	3.2	189
22	Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of Clinical Oncology, 2005, 23, 705-711.	0.8	184
23	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676.	0.6	184
24	Alteration of BIRC3 and multiple other NF-Î¹B pathway genes in splenic marginal zone lymphoma. Blood, 2011, 118, 4930-4934.	0.6	176
25	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	0.6	173
26	The gastric marginal zone B-cell lymphoma of MALT type. Blood, 2000, 96, 410-419.	0.6	172
27	Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma. Leukemia and Lymphoma, 1997, 26, 527-537.	0.6	171
28	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. British Journal of Haematology, 2006, 132, 303-316.	1.2	169
29	Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2012, 30, 2988-2994.	0.8	167
30	The genetics of nodal marginal zone lymphoma. Blood, 2016, 128, 1362-1373.	0.6	147
31	Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Annals of Oncology, 1999, 10, 1023-1034.	0.6	146
32	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nature Medicine, 2017, 23, 1046-1054.	15.2	145
33	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics, 2018, 50, 219-228.	9.4	139
34	The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. British Journal of Haematology, 2009, 146, 64-75.	1.2	136
35	A SNP microarray and FISHâ€based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes and Cancer, 2009, 48, 603-614.	1.5	134
36	Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. Thrombosis and Haemostasis, 2003, 90, 893-897.	1.8	130

#	Article	IF	Citations
37	Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Annals of Oncology, 2009, 20, 1086-1093.	0.6	130
38	Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets. Journal of Immunology, 2005, 175, 7837-7847.	0.4	117
39	Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology, 2011, 47, R11-R23.	1.1	116
40	State-of-the-Art Therapeutics: Marginal-Zone Lymphoma. Journal of Clinical Oncology, 2005, 23, 6415-6420.	0.8	115
41	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia, 2014, 28, 1334-1340.	3.3	115
42	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood, 2009, 114, 4696-4702.	0.6	114
43	Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood, 2002, 99, 2541-2544.	0.6	110
44	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 2014, 123, 1681-1690.	0.6	110
45	Dnmt3a restrains mast cell inflammatory responses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1490-E1499.	3.3	108
46	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	1.2	106
47	Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia, 2009, 23, 1118-1126.	3.3	104
48	Histologic transformation in marginal zone lymphomas. Annals of Oncology, 2015, 26, 2329-2335.	0.6	104
49	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood, 2012, 120, 1274-1281.	0.6	101
50	ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leukemia and Lymphoma, 2007, 48, 410-412.	0.6	99
51	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693.	0.6	98
52	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	0.6	97
53	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Human Pathology, 2009, 40, 645-652.	1.1	96
54	KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica, 2020, 105, 1604-1612.	1.7	96

#	Article	IF	Citations
55	A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 2012, 97, 1085-1091.	1.7	94
56	Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Annals of Oncology, 2008, 19, 835-846.	0.6	93
57	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clinical Cancer Research, 2018, 24, 120-129.	3.2	92
58	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	1.7	91
59	Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas. Clinical Cancer Research, 2014, 20, 5207-5216.	3.2	91
60	Molecular basis of mantle cell lymphoma. British Journal of Haematology, 2004, 124, 130-140.	1.2	89
61	Update on the molecular biology of mantle cell lymphoma. Hematological Oncology, 2006, 24, 22-27.	0.8	89
62	Incidence, risk factors and outcome of histological transformation in follicular lymphoma. British Journal of Haematology, 2012, 157, 188-196.	1.2	89
63	Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene, 2003, 22, 451-455.	2.6	87
64	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: Tâ€cell infiltration and positioning of malignant B cells. International Journal of Cancer, 2010, 127, 2300-2312.	2.3	86
65	The KrÃ¼ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia, 2015, 29, 503-507.	3.3	84
66	CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. , 1999, 26, 176-180.		82
67	Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Research, 2006, 34, 1721-1734.	6.5	81
68	MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1087-1090.	0.6	81
69	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Seminars in Cancer Biology, 2014, 24, 33-42.	4.3	80
70	Gela histological scoring system for postâ€treatment biopsies of patients with gastric <scp>MALT</scp> lymphoma is feasible and reliable in routine practice. British Journal of Haematology, 2013, 160, 47-52.	1.2	79
71	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget, 2017, 8, 7598-7613.	0.8	79
72	A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. Journal of Experimental Medicine, 2006, 203, 1481-1492.	4.2	71

#	Article	IF	Citations
73	Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Annals of Oncology, 1998, 9, 779-781.	0.6	70
74	Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. British Journal of Haematology, 2007, 138, 316-323.	1.2	70
75	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	1.2	70
76	Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. Cancer Research, 2007, 67, 11876-11885.	0.4	67
77	The cellular origin of mantle cell lymphoma. International Journal of Biochemistry and Cell Biology, 2007, 39, 1747-1753.	1.2	67
78	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	1.5	67
79	Genetic lesions in diffuse large B-cell lymphomas. Annals of Oncology, 2015, 26, 1069-1080.	0.6	65
80	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	1.7	64
81	In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Annals of Oncology, 2005, 16, 1169-1176.	0.6	63
82	Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. Genes Chromosomes and Cancer, 2007, 46, 226-238.	1.5	62
83	Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Marine Drugs, 2020, 18, 619.	2.2	62
84	Delving deeper into MALT lymphoma biology. Journal of Clinical Investigation, 2005, 116, 22-26.	3.9	61
85	Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	3.2	60
86	Genomeâ€wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. British Journal of Haematology, 2008, 143, 532-536.	1.2	58
87	Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. British Journal of Haematology, 2006, 134, 27-36.	1.2	56
88	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget, 2015, 6, 3394-3408.	0.8	56
89	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood, 2001, 98, 781-786.	0.6	55
90	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. Haematologica, 2019, 104, e558-e561.	1.7	55

#	Article	IF	Citations
91	Single nucleotide polymorphismâ€arrays provide new insights in the pathogenesis of postâ€transplant diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2010, 149, 569-577.	1.2	53
92	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	0.6	53
93	Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. Journal of Biological Chemistry, 2018, 293, 5600-5612.	1.6	53
94	Marginal-Zone Lymphomas. New England Journal of Medicine, 2022, 386, 568-581.	13.9	53
95	Two types of BCR interactions are positively selected during leukemia development in the EÎ¼-TCL1 transgenic mouse model of CLL. Blood, 2015, 125, 1578-1588.	0.6	52
96	PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. Leukemia and Lymphoma, 2015, 56, 1223-1228.	0.6	52
97	Interaction of CDCP1 with HER2 Enhances HER2-Driven Tumorigenesis and Promotes Trastuzumab Resistance in Breast Cancer. Cell Reports, 2015, 11, 564-576.	2.9	52
98	Bayesian DNA copy number analysis. BMC Bioinformatics, 2009, 10, 10.	1.2	51
99	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	0.6	49
100	Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor-Î´ Activation in Ovarian Cancer Cells. Neoplasia, 2006, 8, 851-IN12.	2.3	48
101	Marginal Zone Lymphomas. Hematology/Oncology Clinics of North America, 2008, 22, 883-901.	0.9	47
102	Genomic lesions associated with a different clinical outcome in diffuse large Bâ€Cell lymphoma treated with Râ€CHOPâ€21. British Journal of Haematology, 2010, 151, 221-231.	1.2	47
103	Gains of MYC locus and outcome in patients with diffuse large Bâ€cell lymphoma treated with Râ€CHOP. British Journal of Haematology, 2011, 155, 274-277.	1.2	47
104	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large Bâ€cell lymphomas. Hematological Oncology, 2010, 28, 62-67.	0.8	46
105	Prognostic impact of monocyte count at presentation in mantle cell lymphoma. British Journal of Haematology, 2013, 162, 465-473.	1.2	46
106	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood, 2013, 122, 2233-2241.	0.6	45
107	Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	3.2	44
108	Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. British Journal of Haematology, 2015, 168, 771-783.	1.2	43

#	Article	IF	Citations
109	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. Clinical Cancer Research, 2019, 25, 5167-5176.	3.2	43
110	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica, 2019, 104, e256-e259.	1.7	43
111	Pyrrolo[2â€²,3â€²:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. Journal of Medicinal Chemistry, 2020, 63, 12023-12042.	2.9	43
112	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	1.7	42
113	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia, 2015, 29, 1390-1401.	3.3	42
114	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	1.2	42
115	An overview on anti-tubulin agents for the treatment of lymphoma patients. , 2020, 211, 107552.		42
116	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget, 2016, 7, 84675-84687.	0.8	42
117	Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALTâ€type gastric lymphoma B cells have undergone an antigen selection process. British Journal of Haematology, 1997, 97, 830-836.	1.2	41
118	Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients. Leukemia and Lymphoma, 2007, 48, 104-108.	0.6	41
119	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. Journal of Translational Medicine, 2009, 7, 76.	1.8	41
120	<scp>MYD88</scp> somatic mutations in <scp>MALT</scp> lymphomas. British Journal of Haematology, 2012, 158, 662-664.	1.2	41
121	Genomeâ€wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. British Journal of Haematology, 2011, 154, 590-599.	1.2	40
122	IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. Blood, 2019, 133, 156-167.	0.6	40
123	Targeting BET bromodomain proteins in cancer: The example of lymphomas. , 2020, 215, 107631.		40
124	MALT lymphomas: pathogenesis can drive treatment. Oncology, 2011, 25, 1134-42, 1147.	0.4	40
125	Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature. Annals of Hematology, 1998, 77, 75-78.	0.8	39
126	Risk factors of central nervous system relapse in mantle cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1908-1914.	0.6	38

#	Article	IF	Citations
127	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. Blood, 2017, 129, 2420-2428.	0.6	38
128	The strength of T cell stimulation determines ILâ€7 responsiveness, secondary expansion, and lineage commitment of primed human CD4⁺ILâ€7R^{hi} T cells. European Journal of Immunology, 2008, 38, 30-39.	1.6	37
129	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Modern Pathology, 2020, 33, 179-187.	2.9	37
130	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Advances, 2020, 4, 4124-4135.	2.5	37
131	Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nature Communications, 2016, 7, 13719.	5.8	36
132	Identification of a potential role forPOU2AF1 andBTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2005, 43, 1-10.	1.5	35
133	PCSF: An R-package for network-based interpretation of high-throughput data. PLoS Computational Biology, 2017, 13, e1005694.	1.5	35
134	Recent advances in understanding the biology of marginal zone lymphoma. F1000Research, 2018, 7, 406.	0.8	35
135	Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Human Pathology, 2007, 38, 787-792.	1.1	34
136	Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica, 2007, 92, 56-65.	1.7	34
137	Patterns of survival of follicular lymphomas at a single institution through three decades. Leukemia and Lymphoma, 2010, 51, 1028-1034.	0.6	33
138	Chromosome band 6q deletion pattern in malignant lymphomas. Cancer Genetics and Cytogenetics, 2006, 165, 106-113.	1.0	32
139	High density genomeâ€wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. British Journal of Haematology, 2008, 141, 622-630.	1.2	32
140	Up-regulation of the hypoxia-inducible factorâ€“1 transcriptional pathway in colorectal carcinomas. Human Pathology, 2008, 39, 1483-1494.	1.1	32
141	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. Leukemia, 2016, 30, 1805-1815.	3.3	32
142	Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends in Cancer, 2021, 7, 823-836.	3.8	32
143	Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer, 2008, 44, 1829-1834.	1.3	31
144	Life expectancy of young adults with follicular lymphoma. Annals of Oncology, 2015, 26, 2317-2322.	0.6	31

#	Article	IF	Citations
145	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 2019, 14, e0212813.	1.1	31
146	Bâ€¢cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. British Journal of Haematology, 2011, 153, 3-14.	1.2	30
147	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematological Oncology, 2011, 29, 91-99.	0.8	30
148	Diffuse large Bâ€¢cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematological Oncology, 2011, 29, 38-41.	0.8	29
149	Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica, 2018, 103, e245-e248.	1.7	29
150	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. Oncotarget, 2015, 6, 5059-5071.	0.8	29
151	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. International Journal of Cancer, 2012, 130, 3006-3010.	2.3	28
152	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. Cancers, 2018, 10, 21.	1.7	28
153	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica, 2019, 104, 1633-1639.	1.7	28
154	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	2.5	28
155	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	0.8	28
156	Mantle cell lymphoma. Current Opinion in Hematology, 2004, 11, 411-418.	1.2	27
157	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. Molecular Cancer Therapeutics, 2019, 18, 1255-1264.	1.9	27
158	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. International Journal of Molecular Sciences, 2020, 21, 1060.	1.8	27
159	Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. Haematologica, 2020, 105, 2584-2591.	1.7	27
160	Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma. Oncogene, 2021, 40, 3799-3814.	2.6	27
161	A novel phage display based platform for exosome diversity characterization. Nanoscale, 2022, 14, 2998-3003.	2.8	27
162	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British Journal of Haematology, 2004, 124, 289-298.	1.2	26

#	Article	IF	Citations
163	Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells. Pathobiology, 2010, 77, 129-135.	1.9	26
164	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Annals of Oncology, 2016, 27, 1123-1128.	0.6	26
165	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nature Communications, 2021, 12, 734.	5.8	26
166	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia, 2019, 33, 2416-2428.	3.3	25
167	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma. Oncotarget, 2016, 7, 58142-58147.	0.8	25
168	In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.. Blood, 2006, 108, 2520-2520.	0.6	25
169	IgVH mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. Journal of Pathology, 2005, 206, 320-327.	2.1	23
170	T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. Frontiers in Oncology, 2018, 8, 317.	1.3	23
171	Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. Leukemia, 2000, 14, 446-448.	3.3	22
172	BCL10 gene mutations rarely occur in lymphoid malignancies. Leukemia, 2000, 14, 905-908.	3.3	22
173	Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. Modern Pathology, 2011, 24, 126-137.	2.9	22
174	A New Network for the Advancement of Marine Biotechnology in Europe and Beyond. Frontiers in Marine Science, 2020, 7, .	1.2	22
175	ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. Oncotarget, 2017, 8, 85068-85084.	0.8	22
176	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. Journal of Translational Medicine, 2012, 10, 18.	1.8	21
177	Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. OncoImmunology, 2015, 4, e1030560.	2.1	21
178	Staining the target: CD37 expression in lymphomas. Blood, 2016, 128, 3022-3023.	0.6	21
179	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open, 2018, 3, e000387.	2.0	21
180	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget, 2016, 7, 79637-79653.	0.8	21

#	Article	IF	Citations
181	Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Oncotarget, 2015, 6, 37229-37240.	0.8	21
182	Cyclin-dependent kinase inhibitor seliciclib showsin vitroactivity in diffuse large B-cell lymphomas. Leukemia and Lymphoma, 2007, 48, 158-167.	0.6	20
183	Molecular and transcriptional characterization of the novel 17p11.2â€p12 amplicon in multiple myeloma. Genes Chromosomes and Cancer, 2007, 46, 1109-1118.	1.5	20
184	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	1.2	20
185	An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens. International Journal of Gynecological Cancer, 2012, 22, 792-800.	1.2	20
186	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematological Oncology, 2012, 30, 46-49.	0.8	20
187	The involvement of microRNA in the pathogenesis of Richter syndrome. Haematologica, 2019, 104, 1004-1015.	1.7	20
188	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Annals of Oncology, 2012, 23, 729-735.	0.6	19
189	Promoter methylation patterns in <scp>R</scp>ichter syndrome affect stemâ€cell maintenance and cell cycle regulation and differ from de novo diffuse large <scp>B</scp>â€cell lymphoma. British Journal of Haematology, 2013, 163, 194-204.	1.2	19
190	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. Cancer Treatment Reviews, 2020, 90, 102090.	3.4	19
191	GPCR Inhibition in Treating Lymphoma. ACS Medicinal Chemistry Letters, 2022, 13, 358-364.	1.3	19
192	Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. Leukemia, 1998, 12, 247-249.	3.3	18
193	Molecular Genetics of Extranodal Marginal Zone (MALT-Type) B-Cell Lymphoma. Leukemia and Lymphoma, 1999, 35, 57-68.	0.6	18
194	Genomeâ€wide high resolution <scp>DNA</scp> profiling of hairy cell leukaemia. British Journal of Haematology, 2013, 162, 566-569.	1.2	18
195	Prognostic models for diffuse large b-cell lymphoma. Hematological Oncology, 2000, 18, 61-73.	0.8	17
196	Toward New Treatments for Mantle-Cell Lymphoma?. New England Journal of Medicine, 2013, 369, 571-572.	13.9	17
197	Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis. Current Opinion in Hematology, 2013, 20, 374-381.	1.2	17
198	Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		17

#	Article	IF	Citations
199	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. Blood, 2011, 118, 1359-1359.	0.6	17
200	Treatment of gastric marginal zone lymphoma of MALT type. Expert Opinion on Pharmacotherapy, 2010, 11, 2141-2152.	0.9	16
201	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiencyâ€related nonâ€Hodgkin lymphomas. British Journal of Haematology, 2011, 152, 777-780.	1.2	16
202	Genome-wide promoter methylation of hairy cell leukemia. Blood Advances, 2019, 3, 384-396.	2.5	16
203	Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget, 2015, 6, 5735-5748.	0.8	16
204	Bayesian network data imputation with application to survival tree analysis. Computational Statistics and Data Analysis, 2016, 93, 373-387.	0.7	15
205	Inhibition of <scp>CHK</scp>1 and <scp>WEE</scp>1 as a new therapeutic approach in diffuse large B cell lymphomas with <scp>MYC</scp> deregulation. British Journal of Haematology, 2018, 181, 129-133.	1.2	15
206	Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. PLoS ONE, 2019, 14, e0215154.	1.1	15
207	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	1.7	14
208	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. Haematologica, 2019, 104, e307-e309.	1.7	14
209	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	1.7	14
210	Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma. Leukemia and Lymphoma, 1999, 36, 147-150.	0.6	13
211	Microsatellite instability in gastric MALT lymphomas and other associated neoplasms. Annals of Oncology, 1999, 10, 783-788.	0.6	13
212	Chlamydia or Not Chlamydia , That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?. Journal of the National Cancer Institute, 2006, 98, 1348-1349.	3.0	13
213	The clinical and biological features of a series of immunophenotypic variant of Bâ€CLL. European Journal of Haematology, 2010, 85, 120-129.	1.1	13
214	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Annals of Oncology, 2013, 24, 1378-1384.	0.6	13
215	The transcription factor ETS1 in lymphomas: friend or foe?. Leukemia and Lymphoma, 2015, 56, 1975-1980.	0.6	13
216	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. Haematologica, 2018, 103, 2049-2058.	1.7	13

#	Article	IF	Citations
217	Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. European Journal of Medicinal Chemistry, 2019, 181, 111545.	2.6	13
218	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. Frontiers in Oncology, 2019, 9, 1301.	1.3	13
219	The management of nongastric MALT lymphomas. Oncology, 2014, 28, 86-93.	0.4	13
220	Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature. Tumori, 1997, 83, 772-775.	0.6	12
221	Management of rare forms of lymphoma. Current Opinion in Oncology, 1998, 10, 377-384.	1.1	12
222	Allelic expression of p73 in human ovarian cancers. Annals of Oncology, 1999, 10, 949-953.	0.6	12
223	Primary Mediastinal Large B-Cell Lymphoma (PMLCL): The Need for Prospective Controlled Clinical Trials. Leukemia and Lymphoma, 1999, 35, 139-146.	0.6	12
224	Integrated profiling of diffuse large Bâ€cell lymphoma with 7q gain. British Journal of Haematology, 2011, 153, 499-503.	1.2	12
225	Single and combined BTK and PI3KÎ´ inhibition with acalabrutinib and ACPâ€319 in preâ€clinical models of aggressive lymphomas. British Journal of Haematology, 2019, 187, 595-601.	1.2	12
226	Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. Non-coding RNA, 2019, 5, 47.	1.3	12
227	Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. British Journal of Cancer, 1997, 76, 36-39.	2.9	11
228	Clonality Assessment in Blood of Patients with Mantle Cell Lymphoma. Leukemia and Lymphoma, 1999, 32, 375-379.	0.6	11
229	Absence of NOTCH1 gene mutations in MALT lymphomas. British Journal of Haematology, 2012, 157, 382-384.	1.2	11
230	Pixantrone: novel mode of action and clinical readouts. Expert Review of Hematology, 2018, 11, 587-596.	1.0	11
231	HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. Scientific Reports, 2020, 10, 7057.	1.6	11
232	Primary Mediastinal Large B-Cell Lymphoma: The Need for Prospective Controlled Clinical Trials. Leukemia and Lymphoma, 1999, 35, 537-544.	0.6	10
233	Association of gastric and Waldeyer's ring lymphoma: a molecular study. , 2000, 18, 15-19.		10
234	A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology, 2009, 27, 154-159.	0.8	10

#	Article	IF	Citations
235	Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 71-76.	0.6	10
236	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 264-273.	1.5	10
237	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood Advances, 2021, 5, 2467-2480.	2.5	10
238	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. Annals of Lymphoma, 2020, 4, 7-7.	4.5	10
239	Resistance to PI3KÎ´ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica, 2022, 107, 2685-2697.	1.7	10
240	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838.	0.6	9
241	Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. British Journal of Haematology, 2012, 156, 354-357.	1.2	9
242	Primary central nervous system lymphoma: Novel precision therapies. Critical Reviews in Oncology/Hematology, 2019, 141, 139-145.	2.0	9
243	Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. Leukemia and Lymphoma, 2019, 60, 3067-3070.	0.6	9
244	STAT6 activation correlates with cerebrospinal fluid ILâ€4 and ILâ€10 and poor prognosis in primary central nervous system lymphoma. Hematological Oncology, 2020, 38, 106-110.	0.8	9
245	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. Frontiers in Oncology, 2020, 10, 584095.	1.3	9
246	Marginal Zone Lymphomas. Cancer Journal (Sudbury, Mass), 2020, 26, 336-347.	1.0	9
247	Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. Veterinary and Comparative Oncology, 2020, 18, 645-655.	0.8	9
248	Genetic alterations underlying the pathogenesis of MALT lymphoma. The Hematology Journal, 2002, 3, 10-13.	2.0	9
249	Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. Annals of Oncology, 1996, 7, 1023-1027.	0.6	8
250	Chromosome instability and translocation t(11;18) in primary gastric marginal zone Bâ€cell lymphoma of MALTâ€type. Hematological Oncology, 2007, 25, 184-188.	0.8	8
251	An integrated Bayesian analysis of LOH and copy number data. BMC Bioinformatics, 2010, 11, 321.	1.2	8
252	Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Targeted Oncology, 2018, 13, 235-245.	1.7	8

#	Article	IF	Citations
253	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. Blood, 2014, 124, 705-705.	0.6	8
254	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. Oncology Reports, 2021, 47, .	1.2	8
255	Palmar-Plantar Erythrodysaesthesia Syndrome Due to 5-Fluorouracil Therapyâ€“An Underestimated Toxic Event?. Acta OncolÃ³gica, 1997, 36, 653-654.	0.8	7
256	Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. Leukemia Research, 2011, 35, 808-813.	0.4	7
257	Genetic alterations in systemic nodal and extranodal nonâ€cutaneous lymphomas derived from mature <scp>T</scp> cells and natural killer cells. Cancer Science, 2012, 103, 1397-1404.	1.7	7
258	The changing paradigm of chronic lymphocytic leukemia management. European Journal of Internal Medicine, 2013, 24, 401-410.	1.0	7
259	Methylation patterns in marginal zone lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 24-31.	0.7	7
260	A Fast Prize-Collecting Steiner Forest Algorithm for Functional Analyses in Biological Networks. Lecture Notes in Computer Science, 2017, , 263-276.	1.0	7
261	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. Journal of Clinical Oncology, 2018, 36, TPS2619-TPS2619.	0.8	7
262	Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices. PLoS ONE, 2013, 8, e79720.	1.1	7
263	Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Deregulating ETS1 and FLI1. Blood, 2011, 118, 1386-1386.	0.6	7
264	ASB2 is a direct target of FLI1 that sustains NF-ÎºB pathway activation in germinal center-derived diffuse large B-cell lymphoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 357.	3.5	7
265	Mantle Cell Lymphoma: New Treatments Targeted to the Biology. Clinical Lymphoma and Myeloma, 2002, 3, 90-96.	2.1	6
266	Another Piece of the MALT Lymphomas Jigsaw. Journal of Clinical Oncology, 2005, 23, 4832-4834.	0.8	6
267	Gains of <scp>CCND</scp>3 gene in ocular adnexal <scp>MALT</scp> lymphomas: an integrated analysis. British Journal of Haematology, 2013, 160, 719-722.	1.2	6
268	<scp>TCL</scp>1A interacts with <scp>TP</scp>63 and enhances the survival of Raji Burkitt lymphoma cell line. British Journal of Haematology, 2018, 183, 509-512.	1.2	6
269	Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. PLoS ONE, 2018, 13, e0208709.	1.1	6
270	Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529. Blood, 2016, 128, 4187-4187.	0.6	6

#	Article	IF	Citations
271	Hierarchy of Human B Cell Regeneration after Rituximab Therapy.. Blood, 2006, 108, 936-936.	0.6	6
272	The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21. Blood, 2008, 112, 480-480.	0.6	6
273	Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. American Journal of Cancer Research, 2020, 10, 572-580.	1.4	6
274	Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades. Cancers, 2022, 14, 1978.	1.7	6
275	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. Lab Animal, 2022, 51, 191-202.	0.2	6
276	The novel atypical retinoid <scp>ST</scp>5589 downâ€regulates Aurora Kinase A and has antiâ€tumour activity in lymphoma preâ€clinical models. British Journal of Haematology, 2015, 171, 378-386.	1.2	5
277	Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. British Journal of Haematology, 2019, 184, 1022-1025.	1.2	5
278	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma. Frontiers in Veterinary Science, 2021, 8, 647009.	0.9	5
279	Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. European Journal of Medicinal Chemistry Reports, 2021, 1, 100004.	0.6	5
280	Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. Leukemia Research, 2011, 35, 1419-1422.	0.4	4
281	Let's give BACH2 a breath of fresh air. Blood, 2017, 130, 696-697.	0.6	4
282	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the <scp>REAL</scp>07 Phase 1â€2 study. British Journal of Haematology, 2018, 182, 453-456.	1.2	4
283	cuRnet: an R package for graph traversing on GPU. BMC Bioinformatics, 2018, 19, 356.	1.2	4
284	Populationâ€based outcome analysis of diffuse large Bâ€cell lymphoma in people living with HIV infection and competent individuals. Hematological Oncology, 2018, 36, 757-764.	0.8	4
285	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type. Cancers, 2020, 12, 1912.	1.7	4
286	Abstract 4275: Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. , 2018, , .		4
287	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. Blood, 2010, 116, 3611-3611.	0.6	4
288	The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. Blood, 2011, 118, 1593-1593.	0.6	4

#	Article	IF	Citations
289	The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). Blood, 2012, 120, 4872-4872.	0.6	4
290	Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors. RSC Medicinal Chemistry, 2020, 11, 665-675.	1.7	4
291	SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. Blood Advances, 2022, 6, 3911-3920.	2.5	4
292	Analysis of BCL-10 gene mutations in ovarian cancer cell lines. Annals of Oncology, 1999, 10, 1259.	0.6	3
293	A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals. Pathobiology, 2007, 74, 264-269.	1.9	3
294	Syk expression patterns differ among B-cell lymphomas. Leukemia Research, 2010, 34, e243-e245.	0.4	3
295	In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. Hematological Oncology, 2011, 29, 164-166.	0.8	3
296	Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies. Current Opinion in Hematology, 2019, 26, 273-280.	1.2	3
297	In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. British Journal of Haematology, 2019, 186, 149-152.	1.2	3
298	Exonâ€“Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation. Non-coding RNA, 2021, 7, 26.	1.3	3
299	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica, 2021, , .	1.7	3
300	Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma.. , 2013, , .		3
301	Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma. , 2019, , .		3
302	Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma. Cancer Research, 2014, 74, 5531-5531.	0.4	3
303	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. Cancer Research, 2015, 75, 2664-2664.	0.4	3
304	Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models. , 2015, , .		3
305	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors. Blood, 2018, 132, 4174-4174.	0.6	3
306	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. Blood, 2019, 134, 2569-2569.	0.6	3

#	Article	IF	Citations
307	Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 801-801.	0.6	3
308	The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. Blood, 2012, 120, 1657-1657.	0.6	3
309	TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL. Blood, 2016, 128, 4035-4035.	0.6	3
310	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. Exploration of Targeted Anti-tumor Therapy, 2021, 2, 586-601.	0.5	3
311	Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAluâ€" Polymerase Chain Reaction. Leukemia and Lymphoma, 2000, 38, 605-610.	0.6	2
312	The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. Leukemia, 2002, 16, 1396-1396.	3.3	2
313	Marginal Zone B-Cell Lymphomas. , 2006, , 381-396.		2
314	Bendamustine in lymphomas: More to combine?. Leukemia and Lymphoma, 2007, 48, 1264-1266.	0.6	2
315	Nonâ€negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. British Journal of Haematology, 2010, 150, 229-232.	1.2	2
316	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Cancer Cell, 2015, 27, 744.	7.7	2
317	Abstract 3853: Humanized NOD/Scid/IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma.. Cancer Research, 2013, 73, 3853-3853.	0.4	2
318	Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models. , 2015, , .		2
319	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922.	0.6	2
320	Long Term Outcome of Gastric MALT Lymphoma Patients Treated with Anti-Helicobacter (Antibiotic and) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	2
321	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). Blood, 2010, 116, 1371-1371.	0.6	2
322	The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents. Blood, 2016, 128, 4185-4185.	0.6	2
323	Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma. Blood, 2016, 128, 4186-4186.	0.6	2
324	Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents. , 2015, , .		2

#	Article	IF	Citations
325	HMGA1 induces EZH2 overexpression in human B-cell lymphomas. American Journal of Cancer Research, 2021, 11, 2174-2187.	1.4	2
326	Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment. Frontiers in Oncology, 0, 12, .	1.3	2
327	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research, 2008, 32, 1628-1632.	0.4	1
328	IGHD3â€3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 149, 299-302.	1.2	1
329	MYC network mutations in highâ€risk chronic lymphocytic leukaemia. Hematological Oncology, 2014, 32, 155-157.	0.8	1
330	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1
331	Abstract 4793: Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma. , 2016, , .		1
332	The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma. Blood, 2014, 124, 3113-3113.	0.6	1
333	BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4495-4495.	0.6	1
334	The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. Blood, 2015, 126, 4005-4005.	0.6	1
335	ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 1755-1755.	0.6	1
336	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. Blood, 2016, 128, 4096-4096.	0.6	1
337	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. Blood, 2010, 116, 2425-2425.	0.6	1
338	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). Blood, 2011, 118, 263-263.	0.6	1
339	Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors. Cancer Research, 2014, 74, 5528-5528.	0.4	1
340	The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. Blood, 2014, 124, 1782-1782.	0.6	1
341	The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2015, 126, 5119-5119.	0.6	1
342	Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax. Blood, 2016, 128, 3017-3017.	0.6	1

#	Article	IF	Citations
343	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. Blood, 2019, 134, 2858-2858.	0.6	1
344	Biological Determinants of Long-Term Survival in Chronic Myelogenous Leukemia Patients Treated with Conventional Chemotherapy. Acta Haematologica, 1997, 97, 187-188.	0.7	0
345	Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping. Gastroenterology, 2000, 118, A1385.	0.6	0
346	MALT lymphoma and other marginal zone lymphomas. , 2001, , 126-140.		0
347	Hematological Oncology: further ahead. Hematological Oncology, 2008, 26, 1-2.	0.8	0
348	Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart. Clinical Oncology and Cancer Research, 2011, 8, 65-70.	0.1	0
349	Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas. Methods in Molecular Biology, 2013, 973, 213-226.	0.4	0
350	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0
351	MALT and other marginal zone lymphomas. , 0, , 104-120.		0
352	568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM). European Journal of Cancer, 2014, 50, 184.	1.3	0
353	Genomeâ€wide <scp>DNA</scp> profiling identifies clonal heterogeneity in marginal zone lymphomas. British Journal of Haematology, 2014, 164, 896-899.	1.2	0
354	PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer, 2016, 69, S39.	1.3	0
355	The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer, 2016, 69, S84.	1.3	0
356	Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines. Methods in Molecular Biology, 2016, 1436, 305-312.	0.4	0
357	A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. Lecture Notes in Computer Science, 2019, , 24-32.	1.0	0
358	Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.. Blood, 2005, 106, 1469-1469.	0.6	0
359	Cyclin-Dependent Kinase Inhibitor Seliciclib Shows In Vitro Activity in Diffuse Large B Cell Lymphomas.. Blood, 2006, 108, 4738-4738.	0.6	0
360	Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. Blood, 2007, 110, 4696-4696.	0.6	0

#	Article	IF	Citations
361	Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia.. Blood, 2007, 110, 4698-4698.	0.6	0
362	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. Blood, 2007, 110, 3089-3089.	0.6	0
363	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. Blood, 2008, 112, 478-478.	0.6	0
364	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Blood, 2008, 112, 778-778.	0.6	0
365	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 3578-3578.	0.6	0
366	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. Blood, 2010, 116, 3601-3601.	0.6	0
367	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. Blood, 2010, 116, 2951-2951.	0.6	0
368	BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). Blood, 2011, 118, 2634-2634.	0.6	0
369	Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers. Blood, 2011, 118, 2660-2660.	0.6	0
370	Abstract 4575: Three-gene diagnostic classifier for ALK negative ALCL. , 2012, , .		0
371	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 712-712.	0.6	0
372	Where Do We Stand in the Genomics of Lymphomas?. , 2013, , 495-541.		0
373	MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma). , 2013, , 111-126.		0
374	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	0.6	0
375	Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes. , 2014, , .		0
376	Abstract CT402: A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL). , 2014, , .		0
377	Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response. , 2014, , .		0
378	Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma. , 2014, , .		0

#	Article	IF	Citations
379	Abstract 2219: STAT3 network dissection in ALK positive Anaplastic Large Cell Lymphomas. , 2014, , .		0
380	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. Blood, 2014, 124, 1679-1679.	0.6	0
381	Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. Blood, 2014, 124, 781-781.	0.6	0
382	Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models. , 2015, , .		0
383	Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features. , 2016, , .		0
384	Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4367-4367.	0.6	0
385	Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). Blood, 2016, 128, 4099-4099.	0.6	0
386	The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines. Blood, 2019, 134, 2574-2574.	0.6	0
387	An epigenetic signature in CD19-CAR T cells predicts clinical outcome. Trends in Cancer, 2022, 8, 81-82.	3.8	0